Patents by Inventor Jin Jen
Jin Jen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8067240Abstract: The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.Type: GrantFiled: November 22, 2010Date of Patent: November 29, 2011Assignees: Esoterix Genetic Laboratories, LLC, Johns Hopkins University School of MedicineInventors: Jin Jen, Gary A. Beaudry, Stephen L. Madden, Arthur H. Bertlesen, David Sidransky
-
Publication number: 20110091892Abstract: The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.Type: ApplicationFiled: November 22, 2010Publication date: April 21, 2011Inventors: Jin Jen, Gary A. Beaudry, Stephen L. Madden, Arthur H. Bertlesen, David Sidransky
-
Patent number: 7846667Abstract: The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.Type: GrantFiled: August 20, 2009Date of Patent: December 7, 2010Assignees: Genzyme Corporation, Johns Hopkins UniversityInventors: Jin Jen, Gary A. Beaudry, Stephen L. Madden, Arthur H. Bertlesen, David Sidransky
-
Patent number: 7709202Abstract: We used hierarchical clustering to examine gene expression profiles generated by serial analysis of gene expression (SAGE) in a total of nine normal lung epithelial cells and non-small cell lung cancers (NSCLC). Separation of normal and tumor samples, as well as histopathological subtypes, was evident using the 3,921 most abundant transcript tags. This distinction remained when just 115 highly differentially expressed transcript tags were used. Furthermore, these 115 transcript tags clustered into groups that were suggestive of the unique biological and pathological features of the different tissues examined. Adenocarcinomas were characterized by high-level expression of small airway-associated or immunologically related proteins, while squamous cell carcinomas overexpressed genes involved in cellular detoxification or antioxidation.Type: GrantFiled: July 27, 2007Date of Patent: May 4, 2010Assignees: The Johns Hopkins University, Genzyne Corporation, The U.S.A. as represented by the Secretary of the HHSInventors: Mariana Nacht, Tatiana Dracheva, David Sidransky, Stephen L Madden, Jin Jen
-
Publication number: 20100062443Abstract: The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.Type: ApplicationFiled: August 20, 2009Publication date: March 11, 2010Inventors: Jin Jen, Gary A. Beaudry, Stephen L. Madden, Arthur H. Bertlesen, David Sidransky
-
Publication number: 20090270265Abstract: We used hierarchical clustering to examine gene expression profiles generated by serial analysis of gene expression (SAGE) in a total of nine normal lung epithelial cells and non-small cell lung cancers (NSCLC). Separation of normal and tumor samples, as well as histopathological subtypes, was evident using the 3,921 most abundant transcript tags. This distinction remained when just 115 highly differentially expressed transcript tags were used. Furthermore, these 115 transcript tags clustered into groups that were suggestive of the unique biological and pathological features of the different tissues examined. Adenocarcinomas were characterized by high-level expression of small airway-associated or immunologically related proteins, while squamous cell carcinomas overexpressed genes involved in cellular detoxification or antioxidation.Type: ApplicationFiled: July 27, 2007Publication date: October 29, 2009Applicants: The United States of America as Represented by the Secretary of Health and Human Services, Genzyme Corporation, The Johns Hopkins University School of MedicineInventors: Mariana NACHT, Tatiana Dracheva, David Sidransky, Stephen Madden, Jin Jen
-
Publication number: 20090124795Abstract: Mitochondrial mutations occur as a product of contact of a person with an environmental pollutant. Mitochondrial mutations are readily detectable in body fluids. Measurement of mitochondrial mutations in body fluids can be used as a dosimeter to monitor exposure to the environmental pollutant. Mitochondrial mutations can also be detected in cancer patients. Probes and primers containing mutant mitochondrial sequences can be used to monitor patient condition.Type: ApplicationFiled: April 10, 2008Publication date: May 14, 2009Applicant: JOHNS HOPKINS UNIVERSITYInventors: Makiko Fliss, David Sidransky, Jin Jen, Kornelia Polyak, Bert Vogelstein, Kenneth W. Kinzler
-
Patent number: 7468425Abstract: We have discovered p40, the shortest variant of a new human p53 homologue (p40/p51/p63/p73H). We have also found that it plays a role in cancer. Low level amplification of the p40 locus accompanied by RNA and protein overexpression was observed in primary lung cancers, and head and neck cancer cell lines. P40 protein overexpression in primary lung tumors was limited to squamous cell carcinoma, tumors known to harbor a high frequency of p53 mutations. Overexpression of p40 in Rat 1a cells led to an increase in soft agar growth and tumor size in mice. We searched for p40 binding proteins using the yeast two-hybrid system. P53 was the most common binding target of the 1.6×106 clones screened from a mouse embryonic library. Moreover, coexpression of p40 and p53 led to a decrease in p53 transcriptional activity. Our results support the notion that p40 plays an oncogenic role in human cancer.Type: GrantFiled: October 22, 2002Date of Patent: December 23, 2008Assignee: The Johns Hopkins UniversityInventors: David Sidransky, Jin Jen, Barry Trink, Edward A. Ratovitski
-
Patent number: 7332590Abstract: We used hierarchical clustering to examine gene expression profiles generated by serial analysis of gene expression (SAGE) in a total of nine normal lung epithelial cells and non-small cell lung cancers (NSCLC). Separation of normal and tumor samples, as well as histopathological subtypes, was evident using the 3,921 most abundant transcript tags. This distinction remained when just 115 highly differentially expressed transcript tags were used. Furthermore, these 115 transcript tags clustered into groups that were suggestive of the unique biological and pathological features of the different tissues examined. Adenocarcinomas were characterized by high-level expression of small airway-associated or immunologically related proteins, while squamous cell carcinomas overexpressed genes involved in cellular detoxification or antioxidation.Type: GrantFiled: August 16, 2002Date of Patent: February 19, 2008Assignees: The United States of America as Represented by the Department of Health and Human Services, Genzyme Corporation, The Johns Hopkins University of MedicineInventors: Mariana Nacht, Tatiana Dracheva, David Sidransky, Stephen Madden, Jin Jen
-
Publication number: 20070218511Abstract: The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell, and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.Type: ApplicationFiled: August 14, 2006Publication date: September 20, 2007Inventors: Jin Jen, Gary Beaudry, Stephen Madden, Arthur Bertlesen, David Sidransky
-
Publication number: 20050136403Abstract: We used hierarchical clustering to examine gene expression profiles generated by serial analysis of gene expression (SAGE) in a total of nine normal lung epithelial cells and non-small cell lung cancers (NSCLC). Separation of normal and tumor samples, as well as histopathological subtypes, was evident using the 3,921 most abundant transcript tags. This distinction remained when just 115 highly differentially expressed transcript tags were used. Furthermore, these 115 transcript tags clustered into groups that were suggestive of the unique biological and pathological features of the different tissues examined. Adenocarcinomas were characterized by high-level expression of small airway-associated or immunologically related proteins, while squamous cell carcinomas overexpressed genes involved in cellular detoxification or antioxidation.Type: ApplicationFiled: August 16, 2002Publication date: June 23, 2005Inventors: Mariana Nacht, Tatiana Dracheva, David Sidransky, Stephen Madden, Jin Jen
-
Publication number: 20040018538Abstract: Mitochondrial mutations occur as a product of contact of a person with an environmental pollutant. Mitochondrial mutations are readily detectable in body fluids. Measurement of mitochondrial mutations in body fluids can be used as a dosimeter to monitor exposure to the environmental pollutant. Mitochondrial mutations can also be detected in cancer patients. Probes and primers containing mutant mitochondrial sequences can be used to monitor patient condition.Type: ApplicationFiled: June 24, 2003Publication date: January 29, 2004Applicant: Johns Hopkins UniversityInventors: Makiko Fliss, David Sidransky, Jin Jen, Kornelia Polyak, Bert Vogelstein, Kenneth W. Kinzler
-
Patent number: 6605433Abstract: Mitochondrial mutations occur as a product of contact of a person with an environmental pollutant. Mitochondrial mutations are readily detectable in body fluids. Measurement of mitochondrial mutations in body fluids can be used as a dosimeter to monitor exposure to the environmental pollutant. Mitochondrial mutations can also be detected in cancer patients. Probes and primers containing mutant mitochondrial sequences can be used to monitor patient condition.Type: GrantFiled: March 15, 2000Date of Patent: August 12, 2003Assignee: The Johns Hopkins UniversityInventors: Makiko Fliss, David Sidransky, Jin Jen, Komelia Polyak, Bert Vogelstein, Kenneth W. Kinzler
-
Publication number: 20030113774Abstract: We have discovered p40, the shortest variant of a new human p53 homologue (p40/p51/p63/p73H). We have also found that it plays a role in cancer. Low level amplification of the p40 locus accompanied by RNA and protein overexpression was observed in primary lung cancers, and head and neck cancer cell lines. P40 protein overexpression in primary lung tumors was limited to squamous cell carcinoma, tumors known to harbor a high frequency of p53 mutations. Overexpression of p40 in Rat 1a cells led to an increase in soft agar growth and tumor size in mice. We searched for p40 binding proteins using the yeast two-hybrid system. P53 was the most common binding target of the 1.6×106 clones screened from a mouse embryonic library. Moreover, coexpression of p40 and p53 led to a decrease in p53 transcriptional activity. Our results support the notion that p40 plays an oncogenic role in human cancer.Type: ApplicationFiled: October 22, 2002Publication date: June 19, 2003Applicant: The Johns Hopkins UniversityInventors: David Sidransky, Jin Jen, Barry Trink, Edward A. Ratovitski
-
Patent number: 6476206Abstract: We have discovered p40, the shortest variant of a new human p53 homologue (p40/p51/p63/p73H). We have also found that it plays a role in cancer. Low level amplification of the p40 locus accompanied by RNA and protein overexpression was observed in primary lung cancers, and head and neck cancer cell lines. P40 protein overexpression in primary lung tumors was limited to squamous cell carcinoma, tumors known to harbor a high frequency of p53 mutations. Overexpression of p40 in Rat 1a cells led to an increase in soft agar growth and tumor size in mice. We searched for p40 binding proteins using the yeast two-hybrid system. P53 was the most common binding target of the 1.6×106 clones screened from a mouse embryonic library. Moreover, coexpression of p40 and p53 led to a decrease in p53 transcriptional activity. Our results support the notion that p40 plays an oncogenic role in human cancer.Type: GrantFiled: March 26, 1999Date of Patent: November 5, 2002Assignee: The Johns Hopkins UniversityInventors: David Sidransky, Jin Jen, Barry Trink, Edward A. Ratovitski
-
Patent number: 6054570Abstract: Over the past decade, it has become clear that tumorigenesis is driven by alterations in genes that control cell growth or cell death. Theoretically, the proteins encoded by these genes provide excellent tools for achieving tumor cell-specific expression. An approach to achieving specific expression of a desired protein in tumor cells is based on the selective expression of such oncoproteins. In outline, an endogenous cellular oncoprotein binds to exogenously introduced gene products, resulting in transcriptional activation of a desired gene. This approach is generally applicable to other diseases in which a particular protein is selectively expressed in disease-affected cells as compared to non-affected cells.Type: GrantFiled: September 30, 1998Date of Patent: April 25, 2000Assignee: The Johns Hopkins UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, Luis da Costa, Jin Jen
-
Patent number: 5866340Abstract: Over the past decade, it has become clear that tumorigenesis is driven by alterations in genes that control cell growth or cell death. Theoretically, the proteins encoded by these genes provide excellent tools for achieving tumor cell-specific expression. An approach to achieving specific expression of a desired protein in tumor cells is based on the selective expression of such oncoproteins. In outline, an endogenous cellular oncoprotein binds to exogenously introduced gene products, resulting in transcriptional activation of a desired gene. This approach is generally applicable to other diseases in which a particular protein is selectively expressed in disease-affected cells as compared to non-affected cells.Type: GrantFiled: March 22, 1996Date of Patent: February 2, 1999Assignee: Johns Hopkins UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, Luis da Costa, Jin Jen